Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 4/20 | 0.49 |
| ▸ | NAAA | Q02083 | 1/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | MARS1 | P56192 | 5/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.39 |
| ▸ | RAD52 | P43351 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL113748 | 1.00 | NOD1 (0.49) | NOD1NAAAEPHX1MARS1TSHR | |
| SCHEMBL8852410 | 1.00 | NOD1 (0.49) | NOD1NAAAEPHX1MARS1TSHR | |
| SCHEMBL8852558 | 1.00 | NOD1 (0.49) | NOD1NAAAEPHX1MARS1TSHR | |
| SCHEMBL111280 | 1.00 | NOD1 (0.49) | NOD1NAAAEPHX1MARS1TSHR | |
| SCHEMBL7780237 | 1.00 | NOD1 (0.49) | NOD1NAAAEPHX1MARS1TSHR | |
| SCHEMBL112341 | 1.00 | NOD1 (0.49) | NOD1NAAAEPHX1MARS1TSHR | |
| SCHEMBL2928691 | 1.00 | NOD1 (0.49) | NOD1NAAAEPHX1MARS1TSHR | |
| SCHEMBL110148 | 1.00 | NOD1 (0.49) | NOD1NAAAEPHX1MARS1TSHR | |
| SCHEMBL8852439 | 1.00 | NOD1 (0.49) | NOD1NAAAEPHX1MARS1TSHR | |
| SCHEMBL2928692 | 1.00 | NOD1 (0.49) | NOD1NAAAEPHX1MARS1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102802605-A | Stable lipid formulations of apoptosis promoters | ABBOTT LAB | 2012-11-28 | — | — | CN | claimed |
| EP-2424499-A1 | STABILIZED LIPID FORMULATION OF APOPTOSIS PROMOTER | Abbott Laboratories (US) | 2012-03-07 | — | — | EP | claimed |
| US-20100278905-A1 | STABILIZED LIPID FORMULATION OF APOPTOSIS PROMOTER | ABBVIE INC. | 2010-11-04 | — | — | US | claimed |
| WO-2010127193-A1 | STABILIZED LIPID FORMULATION OF APOPTOSIS PROMOTER | ABBOTT LABORATORIES (US) | 2010-11-04 | — | — | WO | claimed |
| US-6372788-B1 | — | — | None | — | — | US | disclosed |
| CN-117843540-A | Methionine derivative, preparation method thereof and application of gene vector | 黑龙江八一农垦大学 | 2024-04-09 | — | — | CN | disclosed |
| CN-117843541-A | Lipid compound containing sulfonium cations, preparation method thereof and application of gene vector | 黑龙江八一农垦大学 | 2024-04-09 | — | — | CN | disclosed |
| CN-102655858-B | ABT-263 capsule | ABBVIE (US) | 2015-11-25 | — | — | CN | disclosed |
| CN-102802605-B | Stable lipid formulations of apoptosis promoters | ABBVIE (US) | 2015-08-12 | — | — | CN | disclosed |
| US-8927009-B2 | ABT-263 capsule | ABBVIE INC. (US) | 2015-01-06 | — | — | US | disclosed |
| US-8728516-B2 | Stabilized lipid formulation of apoptosis promoter | ABBVIE INC. (US) | 2014-05-20 | — | — | US | disclosed |
| US-8513243-B2 | ABT-263 crystalline forms | ABBVIE INC. (US) | 2013-08-20 | — | — | US | disclosed |
| CN-1326322-A | Method for supplying bioavailable methionine to cow | AVENTIS ANIMAL NUTRITION SA (FR) | 2001-12-12 | — | — | CN | disclosed |
| EP-1135398-A1 | CYANOPHOSPHONAMIDES AND METHOD FOR PREPARATION | Monsanto Technology LLC (US) | 2001-09-26 | — | — | EP | disclosed |
| EP-1128738-A1 | A METHOD FOR SUPPLYING BIOAVAILABLE METHIONINE TO A COW | AVENTIS ANIMAL NUTRITION S.A. (FR) | 2001-09-05 | — | — | EP | disclosed |
| US-20010008904-A1 | Method for supplying bioavailable methionine to a cow | RHONE-POULENC ANIMAL NUTRITION | 2001-07-19 | — | — | US | disclosed |
| US-6221909-B1 | ADMINISTERING TO THE COW THE ISOPROPYL ESTER OF THE HYDROXY ANALOGUE OF METHIONINE. | RHôNE-POULENC ANIMAL NUTRITION (FR) | 2001-04-24 | — | — | US | disclosed |
| US-6218563-B1 | Cyanophosphonamides and method for preparation | MONSANTO COMPANY | 2001-04-17 | — | — | US | disclosed |
| WO-2000032611-A1 | CYANOPHOSPHONAMIDES AND METHOD FOR PREPARATION | MONSANTO TECHNOLOGY LLC (US) | 2000-06-08 | — | — | WO | disclosed |
| WO-2000028835-A1 | A METHOD FOR SUPPLYING BIOAVAILABLE METHIONINE TO A COW | AVENTIS ANIMAL NUTRITION S.A. (FR) | 2000-05-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100278905-A1 | STABILIZED LIPID FORMULATION OF APOPTOSIS PROMOTER | BCL2, BAX, BCOR | NOD1 2795/4885NAAA 4513/4885EPHX1 4584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.